Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in patients with atrial fibrillation

American Heart Journal

Volumn 170, Issue 3, 2015, Pages 490-497.e1

  Pastori, Daniele ^a   Pignatelli, Pasquale ^a   Farcomeni, Alessio ^b   Cangemi, Roberto ^a   Hiatt, William R ^c   Bartimoccia, Simona ^a   Nocella, Cristina ^a   Vicario, Tommasa ^a   Bucci, Tommaso ^a   Carnevale, Roberto ^a   Lip, Gregory Y H ^d   Violi, Francesco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11 OXOTHROMBOXANE B2; CREATININE; 11-DEHYDRO-THROMBOXANE B2; BIOLOGICAL MARKER; THROMBOXANE B2;

AGED; ANTICOAGULATION; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CREATININE URINE LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; TRANSIENT ISCHEMIC ATTACK; ANALOGS AND DERIVATIVES; DEATH, SUDDEN, CARDIAC; ENZYME LINKED IMMUNOSORBENT ASSAY; INCIDENCE; ITALY; MORTALITY; MYOCARDIAL INFARCTION; RISK ASSESSMENT; STROKE; SURVIVAL RATE; TIME; TRENDS; URINE;

AGED; ATRIAL FIBRILLATION; BIOMARKERS; DEATH, SUDDEN, CARDIAC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; ITALY; MALE; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; RISK ASSESSMENT; STROKE; SURVIVAL RATE; THROMBOXANE B2; TIME FACTORS;

EID: 84941736373     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2015.05.011     Document Type: Article

References (40)

1. E.J. Benjamin, P.A. Wolf, R.B. D'Agostino, and et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study Circulation 98 10 1998 946 952
2. P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation as an independent risk factor for stroke: the Framingham Study Stroke 22 8 1991 983 988
3. H.J. Lin, P.A. Wolf, M. Kelly-Hayes, and et al. Stroke severity in atrial fibrillation. The Framingham Study Stroke 27 10 1996 1760 1764
4. EZ Soliman, MM Safford, P Muntner, Y Khodneva, FZ Dawood, NA Zakai, and et al. Atrial fibrillation and the risk of myocardial infarction JAMA Intern Med 174 1 2014 107 114
5. D Pastori, P Pignatelli, F Angelico, A Farcomeni, M Del Ben, T Vicario, and et al. Incidence of myocardial infarction and vascular death in elderly patients with atrial fibrillation taking anticoagulants: relation to atherosclerotic risk factors Chest 147 6 2015 1644 1650
6. E. Marijon, J.Y. Le Heuzey, S. Connolly, and et al. Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study Circulation 128 20 2013 2192 2201
7. D.A. Lane, S. Raichand, D. Moore, and et al. Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review Health Technol Assess 17 30 2013 1 188
8. M.L. Hansen, R. Sorensen, M.T. Clausen, and et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation Arch Intern Med 170 16 2010 1433 1441
9. B.A. Steinberg, S. Kim, J.P. Piccini, and et al. Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry Circulation 128 7 2013 721 728
10. F. Catella, D. Healy, J.A. Lawson, and et al. 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation Proc Natl Acad Sci U S A 83 16 1986 5861 5865
11. H. Tohgi, S. Konno, K. Tamura, and et al. Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin Stroke 23 10 1992 1400 1403
12. J.W. Eikelboom, J. Hirsh, J.I. Weitz, and et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events Circulation 105 14 2002 1650 1655
13. A.J. Camm, G.Y. Lip, R. De Caterina, and et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association Eur Heart J 33 21 2012 2719 2747
14. G. Mancia, G. De Backer, A. Dominiczak, and et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur Heart J 28 12 2007 1462 1536
15. K.G. Alberti, and P.Z. Zimmet Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation Diabet Med 15 7 1998 539 553
16. K. Dickstein, A. Cohen-Solal, G. Filippatos, and et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur Heart J 29 19 2008 2388 2442
17. K. Thygesen, J.S. Alpert, A.S. Jaffe, and et al. Third universal definition of myocardial infarction J Am Coll Cardiol 60 16 2012 1581 1598
18. Special report from the National Institute of Neurological Disorders and Stroke Classification of cerebrovascular diseases III Stroke 21 4 1990 637 676
19. S. Schulman, C. Kearon, Subcommittee on Control of Anticoagulation of the S, and et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients J Thromb Haemost 3 4 2005 692 694
20. World Medical A World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects Bull World Health Organ 79 4 2001 373 374
21. M.A. Hlatky, P. Greenland, D.K. Arnett, and et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association Circulation 119 17 2009 2408 2416
22. H. Uno, L. Tian, T. Cai, and et al. A unified inference procedure for a class of measures to assess improvement in risk prediction systems with survival data Stat Med 32 14 2013 2430 2442
23. N. Molinari, J.P. Daures, and J.F. Durand Regression splines for threshold selection in survival data analysis Stat Med 20 2 2001 237 247
24. J.W. Eikelboom, G.J. Hankey, J. Thom, and et al. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk Circulation 118 17 2008 1705 1712
25. Y. Wan, C. Heneghan, R. Perera, and et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review Circ Cardiovasc Qual Outcomes 1 2 2008 84 91
26. A.L. Dans, S.J. Connolly, L. Wallentin, and et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial Circulation 127 5 2013 634 640
27. V. Roldan, F. Marin, S. Manzano-Fernandez, and et al. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation? Thromb Haemost 109 5 2013 956 960
28. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, and et al. Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 12 2009 1139 1151
29. M.R. Patel, K.W. Mahaffey, J. Garg, and et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 10 2011 883 891
30. C.B. Granger, J.H. Alexander, J.J. McMurray, and et al. Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 11 2011 981 992
31. E.Z. Soliman, M.M. Safford, P. Muntner, and et al. Atrial fibrillation and the risk of myocardial infarction JAMA Intern Med 174 1 2014 107 114
32. C. Patrono, G. Ciabattoni, and G. Davi Thromboxane biosynthesis in cardiovascular diseases Stroke 21 12 Suppl. 1990 IV130 IV133
33. M. Lamberts, G.H. Gislason, G.Y. Lip, and et al. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study Circulation 129 15 2014 1577 1585
34. P. Pignatelli, R. Carnevale, D. Pastori, and et al. Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2 Circulation 126 1 2012 92 103
35. F. Violi, C. Calvieri, D. Ferro, and et al. Statins as antithrombotic drugs Circulation 127 2 2013 251 257
36. H. Zheng, S. Xue, Z.L. Hu, and et al. The use of statins to prevent postoperative atrial fibrillation after coronary artery bypass grafting: a meta-analysis of 12 studies J Cardiovasc Pharmacol 64 3 2014 285 292
37. K.I. Cho, B.J. Kim, T.J. Cha, and et al. Impact of duration and dosage of statin treatment and epicardial fat thickness on the recurrence of atrial fibrillation after electrical cardioversion Heart Vessel 2014 [in press, Epub ahead of print]
38. F. Santilli, L. Mucci, and G. Davi TP receptor activation and inhibition in atherothrombosis: the paradigm of diabetes mellitus Intern Emerg Med 6 3 2011 203 212
39. C. Patrono Biosynthesis and pharmacological modulation of thromboxane in humans Circulation 81 1 Suppl. 1990 I12 I15 [discussion I22-3]
40. P. Kirchhof, G.Y. Lip, I.C. Van Gelder, and et al. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus conference Thromb Haemost 106 6 2011 1012 1019